Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Author's Avatar
Feb 07, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $20 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the underwriters a 30-day option to purchase up to an additional approximately $3 million of shares of voting common stock. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.